CAR-T细胞疗法「图鉴」

发布于: 雪球转发:8回复:2喜欢:20

出品:医药魔方媒体

文案:白露

绘制及排版:辛格、珂珂

监制:曼话、MS

参考资料 -

[1]Robbie G. Majzner, et al. Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine. (2019)  

[2]Roddie, C., et al. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy. (2019)

[3]Rebecca C. Larson, et al. Recent advances and discoveries in the mechanisms and functions of CAR T cells. (2021)

[4]Robert C. Sterner, et al. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal. (2021)  

[5]Andrew J. Hou, et al. Navigating CAR-T cells through the solid-tumour microenvironment. Nature Reviews Drug Discovery. (2021)  

[6]S. Depil, et al. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nature Reviews Drug Discovery . (2020)  

$复星医药(SH600196)$ $恒瑞医药(SH600276)$ $百时美施贵宝(BMY)$ @今日话题 

全部讨论

2022-10-24 10:41

感觉通用型的副反应应该更小些,半衰期短,没有激活增殖功能的应该更安全。另外通用型CAT-T细胞的激活增殖功能和药厂本身的利益是不是冲突?目前自由竞争阶段,最后谁最好还要看谁技术突破,患者有选择权并最终受益。

2022-10-15 18:58

多一些科普 少一些臆断 挺好